Gema Hernández Ibarburu’s Post

In relapsed or refractory NPM1-mutant acute myeloid leukemia, FLT3-ITD co-mutations are common (49%), and prognosis is poor. In this population, only 14% of patients treated with a FLT3 inhibitor achieve a complete remission. KOMET-008 is a phase 1 trial that will examine ziftomenib, a menin inhibitor, in combination with the FLT3 inhibitor gilteritinib in patients with NPM1-m/FLT3 co-mutations. NPM1-m patients without a FLT3 co-mutation and KMT2A-r patients will receive ziftomenib in combination with FLAG-IDA or LDAC. OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

KOMET-008 is actively recruiting for patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged acute myeloid leukemia. KOMET-008 is a Phase 1 study to assess the safety and recommended Phase 2 dose of ziftomenib in combination with gilteritinib (for patients with a FLT3 co-mutation), FLAG-IDA, or LDAC. To find out more about this trial and the KOMET clinical trial program, visit https://lnkd.in/eUriz4NM

The CD33 protein is a marker of cancerous white blood cells, making it a potential target for immunotherapies in acute myeloid leukemia (AML) patients. 🎯 Every year, 20,000 individuals get diagnosed with AML in the U.S. These patients are usually treated with gemtuzumab ozogamicin; however, this therapy is ineffective in patients with a variant T allele. This antibody, designed by Jatinder Lamba, Ph.D., and her team from the University of Florida College of Pharmacy, enables immunotherapy in these patients. 🔬 License this anti-CD33 antibody for treating AML today. ▶️ https://lnkd.in/eQfvyN9P

The expansive KOMET clinical trial program is studying the potential of menin inhibition with ziftomenib for patients with acute myeloid leukemia (AML). KOMET-001 for relapsed/refractory (R/R) NPM1-m AML KOMET-007 for combination treatment in newly diagnosed or R/R AML with NPM1-m or KMT2A-r KOMET-008 for combination treatment in R/R AML with NPM1-m or KMT2A-r Learn more for your patients: https://lnkd.in/emfyjQyi

An exciting study in NEJM has found that the combination of the drugs, ibrutinib and venetoclax, improves outcomes for chronic lymphocytic leukemia (CLL) compared to standard chemo-immunotherapy. The therapy, guided by measurable residual disease (MRD), led to a notable improvement in progression-free survival and reduced the risk of infection. Furthermore, 58% of patients stopped therapy due to undetectable MRD after three years, which may transform treatments for CLL, the most common type of leukemia in adults. #india #technology #innovation https://lnkd.in/d2DcdjhD

An exciting study in NEJM has found that the combination of the drugs, ibrutinib and venetoclax, improves outcomes for chronic lymphocytic leukemia (CLL) compared to standard chemo-immunotherapy. The therapy, guided by measurable residual disease (MRD), led to a notable improvement in progression-free survival and reduced the risk of infection. Furthermore, 58% of patients stopped therapy due to undetectable MRD after three years, which may transform treatments for CLL, the most common type of leukemia in adults. #india #technology #innovation https://lnkd.in/d2DcdjhD

Acute Myeloid Leukemia (#AML) is the most common acute leukemia affecting adults, and the development of targeted therapies is helping to improve treatment options for patients across molecularly defined subsets. At Servier, we're continuing to drive advancements in AML research as part of our ongoing commitment to improving the lives of patients. Learn more about AML: https://lnkd.in/eFA3_aYi

🔬 Understanding Chronic Lymphocytic Leukemia (CLL): It's crucial to remember that #CLL is a chronic disease, emphasizing the slow-growing nature of the condition. Biomarker testing plays a key role in informing treatment decisions for patients. #BloodCancer #BiomarkerTesting #FoamEd #MedEd

🌟 Exploring hope on the horizon: Zanubrutinib and #ChronicLymphoidLeukemia 🌟 Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disease that is characterized by the proliferation of monoclonal B-cells. It accounts for 25 to 30% of leukemia cases in the United States. In the past, patients were given chemo-immunotherapy regimens based on FCR, BR, or chlorambucil. However, these regimens may cause relapse or recurrence in CLL patients. To overcome this limitation, there is continuous research for the development of newer drugs. 💪 The Food and Drug Administration (FDA) approved zanubrutinib available under the trade name Brukinsa® for the treatment of chronic lymphoid leukemia and small cell lymphomas. Recent studies have shown promising results, highlighting zanubrutinib's efficacy in targeting CLL cells while potentially minimizing side effects. 📈 Dive into our blog @ https://lnkd.in/drdfPESw to delve deeper into zanubrutinib and its potential as a CLL treatment, offering promising effects with manageable side effects. #CLLAwareness #Zanubrutinib #NewHope #FightAgainstCancer #Fludarabine #Cyclophosphamide #Rituximab #Bendamustine #Rituximab #Chlorambucil #BCellReceptor #TargetTherapy #RefractoryCases #ImmuneCells #LymphoidLeukemiaTreatment #BTKInhibitor #LymphoidLeukemiaSymptoms #LymphoidLeukemia #ClinicalTrails #Bhimar #LifeSciences #Healthcare #Informations #Omics #Oncology #Neurology

#WorldCMLDay is on September 22nd! Every day till then, I will highlight some important information about Chronic Myeloid Leukemia (CML). Overall Survival : -With the advent of tyrosine kinase inhibitors (TKIs), the overall survival rate for CML patients has improved dramatically. Today, most CML patients can expect to live a normal lifespan. -For example, the 5-year overall survival (OS) rate for CML patients with TKI therapy is now over 90%. The 10-year OS rate is 85-90%. -However, the overall survival rate for CML patients can still be affected by a number of factors, including the patient's age at diagnosis, the type of TKI used, and the presence of any other medical conditions. References : https://lnkd.in/ebkByZsq https://lnkd.in/e7V9ma28 #bloodcancerawarenessmonth #fightcancer